Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14)

Bone Marrow Transplantation volume 40, pages 1033–1037 (2007)Cite this article

Abstract

Lack of CD56 expression was reported to be associated with a poor prognosis in multiple myeloma (MM) patients treated with conventional chemotherapy. Aim of our retrospective study was to analyse whether CD56 expression on MM cells reveals as a prognostic factor in patients treated with high-dose chemotherapy. MM cells of 99 patients prior to treatment with high-dose chemotherapy were analysed for CD56 expression by flow cytometry. Multivariable analysis of event-free survival in these patients showed no statistically significant difference between the CD56− (n=28) and the CD56+ (n=71) group. The lack of CD56 expression on MM cells of these patients correlated significantly with the presence of translocation (11;14) (t(11;14)) (estimated correlation coefficient=0.655 95%, confidence interval (0.481; 0.779)). In summary, our results indicate that lack of CD56 expression on MM cells is not a prognostic marker in patients treated with high-dose chemotherapy, but is associated with t(11;14).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Blade J, Vesole DH, Gertz M . High-dose therapy in multiple myeloma. Blood 2003; 102: 3469–3470.

    Article  CAS  Google Scholar 

  2. Kyle RA, Rajkumar SV . Multiple myeloma. N Engl J Med 2004; 351: 1860–1873.

    Article  CAS  Google Scholar 

  3. Rutishauser U, Acheson A, Hall AK, Mann DM, Sunshine J . The neural cell adhesion molecule (NCAM) as a regulator of cell–cell interactions. Science 1988; 240: 53–57.

    Article  CAS  Google Scholar 

  4. Blaheta RA, Hundemer M, Mayer G, Vogel JU, Kornhuber B, Cinatl J et al. Expression level of neural cell adhesion molecule (NCAM) inversely correlates with the ability of neuroblastoma cells to adhere to endothelium in vitro. Cell Commun Adhes 2002; 9: 131–147.

    Article  CAS  Google Scholar 

  5. Blaheta RA, Beecken WD, Engl T, Jonas D, Oppermann E, Hundemer M et al. Human cytomegalovirus infection of tumor cells downregulates NCAM (CD56): a novel mechanism for virus-induced tumor invasiveness. Neoplasia 2004; 6: 323–331.

    Article  CAS  Google Scholar 

  6. Sahara N, Takeshita A, Shigeno K, Fujisawa S, Takeshita K, Naito K et al. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol 2002; 117: 882–885.

    Article  Google Scholar 

  7. Van CB, Durie BG, Spier C, De WM, Van RI, Vela E et al. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood 1990; 76: 377–382.

    Google Scholar 

  8. Harada H, Kawano MM, Huang N, Harada Y, Iwato K, Tanabe O et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 1993; 81: 2658–2663.

    CAS  PubMed  Google Scholar 

  9. Lin P, Owens R, Tricot G, Wilson CS . Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004; 121: 482–488.

    Article  Google Scholar 

  10. Rawstron A, Barrans S, Blythe D, Davies F, English A, Pratt G et al. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression. Br J Haematol 1999; 104: 138–143.

    Article  CAS  Google Scholar 

  11. Martin P, Santon A, Bellas C . Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis. Histopathology 2004; 44: 375–380.

    Article  CAS  Google Scholar 

  12. Ely SA, Knowles DM . Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol 2002; 160: 1293–1299.

    Article  Google Scholar 

  13. Kremer M, Ott G, Nathrath M, Specht K, Stecker K, Alexiou C et al. Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis. J Pathol 2005; 205: 92–101.

    Article  CAS  Google Scholar 

  14. Pellat-Deceunynck C, Barille S, Jego G, Puthier D, Robillard N, Pineau D et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia 1998; 12: 1977–1982.

    Article  CAS  Google Scholar 

  15. Pellat-Deceunynck C, Barille S, Puthier D, Rapp MJ, Harousseau JL, Bataille R et al. Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. Cancer Res 1995; 55: 3647–3653.

    CAS  PubMed  Google Scholar 

  16. Barille S, Collette M, Bataille R, Amiot M . Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood 1995; 86: 3151–3159.

    CAS  PubMed  Google Scholar 

  17. Chang H, Samiee S, Yi QL . Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant. Leuk Lymphoma 2006; 47: 43–47.

    Article  CAS  Google Scholar 

  18. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86: 4250–4256.

    CAS  PubMed  Google Scholar 

  19. Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 2002; 99: 3735–3741.

    Article  CAS  Google Scholar 

  20. Pruneri G, Fabris S, Baldini L, Carboni N, Zagano S, Colombi MA et al. Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). Am J Pathol 2000; 156: 1505–1513.

    Article  CAS  Google Scholar 

  21. Garand R, Avet-Loiseau H, Accard F, Moreau P, Harousseau JL, Bataille R . t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia 2003; 17: 2032–2035.

    Article  CAS  Google Scholar 

  22. Soverini S, Cavo M, Cellini C, Terragna C, Zamagni E, Ruggeri D et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood 2003; 102: 1588–1594.

    Article  CAS  Google Scholar 

  23. Ried T, Lengauer C, Cremer T, Wiegant J, Raap AK, van der PM et al. Specific metaphase and interphase detection of the breakpoint region in 8q24 of Burkitt lymphoma cells by triple-color fluorescence in situ hybridization. Genes Chromosomes Cancer 1992; 4: 69–74.

    Article  CAS  Google Scholar 

  24. Gill R . Understanding Cox's regression model. Experientia Suppl 1982; 41: 187–199.

    CAS  PubMed  Google Scholar 

  25. Mateo G, Castellanos M, Rasillo A, Gutierrez NC, Montalban MA, Martin ML et al. Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res 2005; 11: 3661–3667.

    Article  CAS  Google Scholar 

  26. Zojer N, Konigsberg R, Ackermann J, Fritz E, Dallinger S, Kromer E et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000; 95: 1925–1930.

    CAS  PubMed  Google Scholar 

  27. Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002; 100: 1579–1583.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was funded in part by the Tumorzentrum Heidelberg/Mannheim and the Dietmar-Hopp-Stiftung.

Author information

Author notes

  1. M Hundemer and U Klein: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany

    M Hundemer, U Klein, D Hose, M-S Raab, F W Cremer, C Heiß, M Moos, A D Ho & H Goldschmidt

  2. National Center for Tumor Diseases Heidelberg, Heidelberg, Germany

    D Hose & H Goldschmidt

  3. Institute of Human Genetics, Heidelberg University Medical Centre, Heidelberg, Germany

    A Jauch

  4. Department of Biostatistics, German Cancer Research Centre, Heidelberg, Germany

    A Benner & C Heiß

Authors
  1. M Hundemer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Hose
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M-S Raab
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F W Cremer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Jauch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Benner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C Heiß
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Moos
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A D Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. H Goldschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H Goldschmidt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hundemer, M., Klein, U., Hose, D. et al. Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14). Bone Marrow Transplant 40, 1033–1037 (2007). https://doi.org/10.1038/sj.bmt.1705857

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705857

Keywords

This article is cited by

Search

Advanced search

Quick links